EDSA

Edesa Biotech, Inc. NASDAQ Listed Jun 21, 2010

Healthcare ·Biotechnology ·CA · edesabiotech.com

$4.72

+2.61% vs $4.60

Mkt Cap $45.5M

52w Low $0.72 20.4% of range 52w High $20.32

50d MA $6.10 200d MA $5.19

P/E (TTM) —

EV/EBITDA —

P/B 2.1x

Debt/Equity 0.0x

ROE -56.0%

P/FCF -3.6x

RSI (14) 40.10

ATR (14) $0.63

Beta -0.68

50d MA $6.10

200d MA $5.19

Avg Volume 85.4K

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

SIC Code

2834

CIK (SEC)

1540159

Phone

289-800-9600

100 Spy Court · Markham, ON L3R 5H6 · CA

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Aug 13, 2026	AMC	-0.44	-0.60	-36.4%	5.43	+4.8%	-1.5%	+5.6%	+1.1%	+0.7%	-17.2%	—
May 14, 2026	AMC	-0.24	-0.49	-104.2%	14.61	+0.0%	-10.7%	-31.0%	+32.8%	-8.5%	-0.5%	—
Feb 13, 2026	AMC	-0.28	-0.28	+0.0%	1.02	+10.8%	+0.0%	-2.7%	-9.0%	-11.4%	+12.4%	—
Dec 12, 2025	AMC	-0.27	-0.32	-18.5%	1.74	-2.9%	-16.1%	+2.1%	+2.0%	-3.3%	+0.7%	—
Aug 8, 2025	AMC	-0.26	-0.25	+3.8%	2.12	-0.9%	-0.5%	+2.8%	+0.9%	+3.2%	-0.9%	—
May 14, 2025	AMC	-0.30	-0.30	+0.0%	2.03	-1.5%	-1.5%	+1.5%	-1.0%	+1.0%	-1.5%	—
Feb 14, 2025	AMC	-0.31	-0.48	-54.8%	2.69	-14.5%	-7.1%	+1.6%	-1.6%	-2.8%	-7.8%	—
Dec 13, 2024	AMC	-0.54	-0.29	+46.3%	1.94	-3.1%	-2.1%	-1.6%	-2.7%	-3.8%	-1.1%	—
Aug 9, 2024	AMC	-0.58	-0.52	+10.3%	4.84	-5.0%	-4.8%	-1.7%	-0.9%	-3.8%	+1.4%	—
May 10, 2024	AMC	-0.69	-0.58	+15.9%	4.61	+0.0%	-3.9%	+2.3%	-0.4%	+0.2%	+0.7%	—
Feb 9, 2024	AMC	-1.21	-0.54	+55.4%	4.83	+5.2%	+7.9%	-4.0%	+13.4%	-0.4%	-5.0%	—
Dec 15, 2023	AMC	-0.71	-0.60	+15.5%	5.19	-8.3%	-7.5%	+3.8%	-2.2%	-1.0%	+4.6%	—
Aug 9, 2023	AMC	-1.19	-0.70	+41.2%	6.44	+4.3%	-3.3%	+0.0%	-2.2%	-2.3%	-1.2%	—
May 11, 2023	AMC	-1.19	-0.84	+29.4%	6.65	+4.2%	-7.4%	+0.0%	-3.4%	+10.6%	-3.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.86	$1.80	-3.2%	-6.5%	-2.3%	-0.6%	+0.6%	+0.6%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.38	$2.49	+4.6%	+0.0%	+0.4%	+2.1%	-2.5%	+3.4%
Nov 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.15	$3.25	+3.2%	+5.1%	-0.3%	+4.5%	-2.0%	+3.6%
Nov 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.80	$3.13	+11.8%	+12.9%	+2.8%	-3.4%	+0.3%	+5.1%
Oct 12	Brookline Capital	Maintains	Buy → Buy	—	$2.70	$3.00	+11.1%	+80.7%	-18.9%	+6.8%	-2.6%	-0.5%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.09	$6.02	-1.1%	-2.3%	-1.2%	+1.2%	+2.4%	-2.3%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.23	$6.02	-3.4%	-2.2%	-2.3%	-1.2%	+1.2%	+2.4%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.44	$6.44	+0.0%	+7.6%	-9.1%	+1.1%	-1.1%	+1.1%
May 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.37	$6.44	+1.1%	+1.1%	+7.6%	-9.1%	+1.1%	-1.1%
Mar 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.75	$8.47	-3.2%	-4.0%	+2.5%	-19.5%	+9.1%	-3.7%
Feb 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.80	$9.87	+0.7%	-0.7%	+3.6%	+2.1%	-2.7%	+2.8%
Dec 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$39.97	$42.98	+7.5%	-0.4%	+2.3%	+5.2%	+5.7%	-5.9%

Data updated apr 25, 2026 6:27am · Source: financialmodelingprep.com